Edition:
United Kingdom

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

8.03USD
7:46pm BST
Change (% chg)

$-0.10 (-1.23%)
Prev Close
$8.13
Open
$8.12
Day's High
$8.20
Day's Low
$8.02
Volume
46,651
Avg. Vol
209,478
52-wk High
$17.96
52-wk Low
$7.82

Chart for

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.15
Market Cap(Mil.): $1,239.53
Shares Outstanding(Mil.): 105.58
Dividend: --
Yield (%): --

Financials

  LXRX.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.33 -- --
ROI: -42.10 1.58 14.38
ROE: -85.52 2.41 16.07

BRIEF-‍Lexicon announces EMA acceptance of MAA for Sotagliflozin to treat adults with Type 1 Diabetes​

* ‍LEXICON PHARMACEUTICALS ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES​ Source text for Eikon: Further company coverage:

29 Mar 2018

BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes

* LEXICON PHARMACEUTICALS ANNOUNCES REGULATORY SUBMISSIONS FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES

26 Mar 2018

BRIEF-Lexicon Pharmaceuticals Q4 Loss Per Share $0.27

* LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

22 Feb 2018

BRIEF-Biopharma Credit Says Enetered Into Term Loan Agreement For Up To US$200 Mln With Lexicon Pharmaceuticals

* BIOPHARMA CREDIT PLC SAYS ENETERED INTO A DEFINITIVE TERM LOAN AGREEMENT FOR UP TO US$200 MILLION WITH LEXICON PHARMACEUTICALS, INC. Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

05 Dec 2017

BRIEF-Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing

* LEXICON PHARMACEUTICALS SECURES UP TO $200 MILLION NON-DILUTIVE TERM LOAN FINANCING

05 Dec 2017

BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.29

* Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update

08 Nov 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.67 -0.38
Roche Holding Ltd. (ROG.S) CHF217.75 -1.45
Roche Holding Ltd. (RO.S) CHF222.60 -1.20
Merck & Co., Inc. (MRK.N) $59.33 -0.76
Bayer AG (BAYGn.DE) €97.47 -0.50
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.87 +0.45
Eli Lilly and Co (LLY.N) $80.53 +0.44
Abbott Laboratories (ABT.N) $58.29 -0.02
Bristol-Myers Squibb Co (BMY.N) $51.40 -0.18

Earnings vs. Estimates